Researchers treated five patients with a single intravitreal injection of 4.0 mg of VEGF Trap-Eye, and followed them for six weeks. No ocular toxicity was observed. At six weeks, four of the five patients showed improvement in foveal thickness (median 31 percent reduction from baseline) and improvement in BCVA (median improvement of three letters). Compared with Lucentis, VEGF Trap-Eye has a longer half-life after intraocular injection, a higher binding affinity to VEGF-A, and it binds to other members of the VEGF family, including placental growth. British Journal of Ophthalmology, February 2009

Dr. Sarbjit Singh
EYE FOR EXCELLENCE

AsianOphthalmology